Thus, our study strongly supports the positioning of NF-κB as a master regulator that may serve as a therapeutic target, whose inhibition may lead to significant downregulation of inflammatory, pro-cancerous events in the entire tumor. This evidence concerns the gene NFKB1 and neoplasm.